Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563637 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2HPGDEPHX2NR1H2 | |
| SCHEMBL31230956 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL1709866 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL6914295 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL18693034 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL6634407 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL18842296 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL15368820 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL20137006 | 0.83 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL4975667 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | USP2 128/4885SMN1; SMN2 3957/4885HPGD 2055/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | USP2 255/4885SMN1; SMN2 3271/4885HPGD 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.